Live News

Targeting HER2 in Gastroesophageal Cancer: A New Appetite for an Old Plight

The incidence of gastroesophageal cancers is rising, driven, in part, by an increasing burden of risk factors of obesity a...

Drugs

0 0

Current and Emerging Therapeutic Strategies for the Management of Neurotrophic Keratitis

Neurotrophic keratitis is a rare eye condition characterised by reduced or absent corneal sensation. This leads to impaire...

Drugs

0 0

Antibacterials with Novel Chemical Scaffolds in Clinical Development

The rise of antimicrobial resistance represents a significant global health threat, driven by the diminishing efficacy of ...

Drugs

0 0

Emerging Immunotherapies for Disease Modification of Type 1 Diabetes

Type 1 diabetes mellitus (T1DM) is characterized by the progressive, autoimmune-mediated destruction of β cells. As s...

Drugs

0 0

Buprenorphine Pharmacodynamics: A Bridge to Understanding Buprenorphine Clinical Benefits

Buprenorphine is an agonist at the mu opioid receptor (MOR) and antagonist at the kappa (KOR) and delta (DOR) receptors an...

Drugs

0 0

Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology

Due to the lack of a comprehensive pharmacology test set, evaluating the potential and value of large language models (LLM...

Drugs

0 0

Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review

Tuberculosis (TB) is the leading cause of death from a single infectious agent. The burden is highest in some low- and mid...

Drugs

0 0

Inavolisib: First Approval

Inavolisib (Itovebi™) is an orally administered, phosphatidylinositol-3-kinase alpha (PI3Kα) inhibitor being de...

Drugs

0 0

Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have revolutionized the treatment of hormone-receptor positive (HR+), HER...

Drugs

0 0

Marstacimab: First Approval

Marstacimab (marstacimab-hncq; HYMPAVZI™) is a subcutaneously administered human monoclonal immunoglobulin G1 antibo...

Drugs

0 0

The Future of Microbiome Therapeutics

The human microbiome exerts profound influence over various biological processes within the body. Unlike many host determi...

Drugs

0 0

Ebronucimab: First Approval

Ebronucimab (伊喜宁®) is a subcutaneous fully human anti-proprotein convertase subtilisin/kexin typ...

Drugs

0 0

Correction: Tegileridine: First Approval

Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a sh...

Drugs

0 0

Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses

Although paracetamol (acetaminophen) combined with other analgesics can reduce pain intensity in some pain conditions, its...

Drugs

0 0

Tunlametinib: First Approval

Tunlametinib (科露平®) is an oral, selective, mitogen-activated protein kinase kinase 1 and 2 (MEK ...

Drugs

0 0

Zolbetuximab: First Approval

Zolbetuximab (VYLOY™), a recombinant, chimeric, anti-claudin 18.2 (CLDN18.2) monoclonal antibody (mAb), is being dev...

Drugs

0 0

Mavorixafor: First Approval

Mavorixafor (XOLREMDI™) is an oral, selective C-X-C chemokine receptor 4 (CXCR4) antagonist developed by X4 Pharmace...

Drugs

0 0

Bone Fragility in Diabetes and its Management: A Narrative Review

Bone fragility is a serious yet under-recognised complication of diabetes mellitus (DM) that is associated with significan...

Drugs

0 0

Elafibranor: First Approval

Elafibranor (IQIRVO®) is a first-in-class peroxisome proliferator-activated receptor (PPAR) agonist being developed b...

Drugs

0 0

Anticoagulation in Chronic Kidney Disease

The nuanced landscape of anticoagulation therapy in patients with chronic kidney disease (CKD) presents a formidable chall...

Drugs

0 0

Imetelstat: First Approval

Imetelstat (RYTELO™), an oligonucleotide telomerase inhibitor, is being developed by Geron Corporation for the treat...

Drugs

0 0

Ensifentrine: First Approval

Ensifentrine, an inhaled, selective phosphodiesterase (PDE) 3 and PDE4 inhibitor, is being developed by Verona Pharma plc ...

Drugs

0 0

Cefepime–Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination

Taniborbactam (formerly known as VNRX-5133) is a novel bicyclic boronate β-lactamase inhibitor of serine β-lacta...

Drugs

0 0

Impact of CYP2C19 Genotype Status on Clinical Outcomes in Patients with Symptomatic Coronary Artery Disease, Stroke, and Peripheral Arterial Disease: A Systematic Review and Meta-Analysis

Clopidogrel is widely used for the secondary prevention of atherothrombotic events in patients with coronary artery diseas...

Drugs

0 0

Long-Term Safety and Efficacy Evaluation of Travoprost Intracameral Implant Based on Pooled Analyses from Two Phase III Trials

The purpose of this study was to conduct and interpret a pooled 12-month analysis of two prospective, multi-center, random...

Drugs

0 0

Dose Individualisation of Antimicrobials from a Pharmacometric Standpoint: The Current Landscape

Successful antimicrobial therapy depends on achieving optimal drug concentrations within individual patients. Inter-patien...

Drugs

0 0

Donanemab: First Approval

Donanemab (donanemab-azbt; KisunlaTM) is an amyloid β-directed antibody developed by Eli Lilly and Company for the tr...

Drugs

0 0

Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials

Nonalcoholic fatty liver disease (NAFLD), currently referred to as metabolic dysfunction-associated steatotic liver diseas...

Drugs

0 0

The Pharmacological Landscape for Fatty Change of the Pancreas

The quest for medications to reduce intra-pancreatic fat deposition is now quarter a century old. While no specific medica...

Drugs

0 0

Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain

An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate [Myfembree®...

Drugs

0 0

Categories

Channels

SCI Abstract